The choice of prodrugs for gene directed enzyme prodrug therapy of cancer
Prodrugs are chemicals that are pharmacodynamically and toxicologically inert but which can be converted to highly active species. In cancer chemotherapy, enzyme activated prodrugs have been effective against certain animal tumours. However, in the clinic it has been found that human tumours contain...
Saved in:
Published in | Gene therapy Vol. 2; no. 10; p. 702 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
England
01.12.1995
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Prodrugs are chemicals that are pharmacodynamically and toxicologically inert but which can be converted to highly active species. In cancer chemotherapy, enzyme activated prodrugs have been effective against certain animal tumours. However, in the clinic it has been found that human tumours containing appropriately high levels of the activating enzymes were rare and not associated with any particular type of tumour. Gene directed enzyme prodrug therapy (GDEPT) attempts to overcome this problem by killing tumour cells by the activation of a prodrug after the gene encoding for an activating enzyme has been targeted to the malignant cell. Here we summarise the various enzyme/prodrug systems that have been proposed for cancer therapy and comment on their suitability for GDEPT. This is because systems developed for other applications such as antibody directed enzyme prodrug therapy (ADEPT) may not be suitable for GDEPT. What is required are nontoxic prodrugs that can be converted intracellularly to highly cytotoxic metabolites that are not cell cycle specific in their mechanism of action. The active drugs released should also be readily diffusible and exert a bystander effect. Alkylating agents best meet these criteria. An example of a suitable enzyme/prodrug system may be a bacterial nitroreductase that can convert a relatively nontoxic monofunctional alkylating agent to a difunctional alkylating agent that is some ten thousand times more cytotoxic. |
---|---|
AbstractList | Prodrugs are chemicals that are pharmacodynamically and toxicologically inert but which can be converted to highly active species. In cancer chemotherapy, enzyme activated prodrugs have been effective against certain animal tumours. However, in the clinic it has been found that human tumours containing appropriately high levels of the activating enzymes were rare and not associated with any particular type of tumour. Gene directed enzyme prodrug therapy (GDEPT) attempts to overcome this problem by killing tumour cells by the activation of a prodrug after the gene encoding for an activating enzyme has been targeted to the malignant cell. Here we summarise the various enzyme/prodrug systems that have been proposed for cancer therapy and comment on their suitability for GDEPT. This is because systems developed for other applications such as antibody directed enzyme prodrug therapy (ADEPT) may not be suitable for GDEPT. What is required are nontoxic prodrugs that can be converted intracellularly to highly cytotoxic metabolites that are not cell cycle specific in their mechanism of action. The active drugs released should also be readily diffusible and exert a bystander effect. Alkylating agents best meet these criteria. An example of a suitable enzyme/prodrug system may be a bacterial nitroreductase that can convert a relatively nontoxic monofunctional alkylating agent to a difunctional alkylating agent that is some ten thousand times more cytotoxic. |
Author | Connors, T A |
Author_xml | – sequence: 1 givenname: T A surname: Connors fullname: Connors, T A organization: Centre for Polymer Therapeutics, School of Pharmacy, London, UK |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/8750009$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j8tqwzAURLVISZO0n1DQDxj0sh7LEvoIBLJJ10G-uopdasnIzsL9-qY0XQ0Dc4aZNVmknHBBVsxpVxku7D1Zj-MnY0wZK5ZkaU19NW5FdscWKbS5A6Q50qHkUC7nkcZc6BkT0tAVhAkDxfQ99_ifoFOLxQ_zLwQ-AZYHchf914iPN92Qj9eX4_a92h_edtvnfTUIaaYqeoW2QeW4CaaRQfsaFLeaqeBkozx3UuhohJOcSwm1dgDhutYz0NHWVmzI01_vcGl6DKehdL0v8-l2SfwAaXlIRA |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine |
ExternalDocumentID | 8750009 |
Genre | Research Support, Non-U.S. Gov't Journal Article Review |
GroupedDBID | --- -Q- .55 .GJ 0R~ 29H 2WC 36B 39C 3V. 4.4 406 53G 5GY 70F 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8R4 8R5 AACDK AANZL AASML AATNV AAYZH AAZLF ABAKF ABAWZ ABDBF ABJNI ABLJU ABUWG ABZZP ACAOD ACGFS ACKTT ACMJI ACPRK ACRQY ACZOJ ADBBV ADFRT ADHDB AEFQL AEJRE AEMSY AENEX AEVLU AEXYK AFBBN AFKRA AFSHS AGAYW AGEZK AGHAI AGQEE AHMBA AHSBF AIGIU AILAN AJRNO ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS AMYLF ASPBG AVWKF AXYYD AZFZN AZQEC B0M BAWUL BBNVY BENPR BHPHI BKKNO BPHCQ BVXVI CAG CCPQU CGR COF CS3 CUY CVF DIK DNIVK DPUIP DU5 DWQXO E3Z EAD EAP EBC EBLON EBS ECM EE. EIF EIOEI EJD EMB EMK EMOBN EPL ESX F5P FDQFY FEDTE FERAY FIGPU FIZPM FSGXE FYUFA GNUQQ GUQSH HCIFZ HMCUK HVGLF HZ~ IAO IEA IGG IHR IHW INH INR ISR ITC IWAJR JSO JZLTJ KQ8 LK8 M1P M2O M7P N9A NAO NPM NQJWS O9- OK1 OVD PQQKQ PROAC PSQYO Q2X RNS RNT RNTTT SNX SNYQT SOHCF SRMVM SV3 SWTZT TAOOD TBHMF TDRGL TEORI TR2 TSG TUS UDS UKHRP W2D X7M Y6R ~8M |
ID | FETCH-LOGICAL-p237t-fa4e8be4917d7b3d6a5c418604d93b4a19326f72931133c569ccd750a0c6f8582 |
ISSN | 0969-7128 |
IngestDate | Tue Oct 15 23:16:02 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-p237t-fa4e8be4917d7b3d6a5c418604d93b4a19326f72931133c569ccd750a0c6f8582 |
PMID | 8750009 |
ParticipantIDs | pubmed_primary_8750009 |
PublicationCentury | 1900 |
PublicationDate | 1995-12-01 |
PublicationDateYYYYMMDD | 1995-12-01 |
PublicationDate_xml | – month: 12 year: 1995 text: 1995-12-01 day: 01 |
PublicationDecade | 1990 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Gene therapy |
PublicationTitleAlternate | Gene Ther |
PublicationYear | 1995 |
SSID | ssj0004782 |
Score | 1.8986379 |
SecondaryResourceType | review_article |
Snippet | Prodrugs are chemicals that are pharmacodynamically and toxicologically inert but which can be converted to highly active species. In cancer chemotherapy,... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 702 |
SubjectTerms | Antineoplastic Agents - administration & dosage Antineoplastic Agents - metabolism Antineoplastic Agents - therapeutic use Biotransformation Enzymes - administration & dosage Enzymes - biosynthesis Enzymes - therapeutic use Genetic Therapy - methods Humans Neoplasms - drug therapy Prodrugs - administration & dosage Prodrugs - metabolism Prodrugs - therapeutic use |
Title | The choice of prodrugs for gene directed enzyme prodrug therapy of cancer |
URI | https://www.ncbi.nlm.nih.gov/pubmed/8750009 |
Volume | 2 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ07a8MwEMdF09KSpfQV-kZDt-BiW5IfYyktaSGZEsgWJFnqFCcEd2g-fU8POya09LGYYMnGuZ99Psn63yF0lwumVZjkgY6NJEfFOhBaiiBLKGdcmJw3Rjs8HCWDCX2dsukmm4VVl1TiXq6_1JX8hyrsA65GJfsHss1JYQf8Br6wBcKw_TVjcF_wrNuFy-ALV-9vNsGCqYys-u59BSGlKtcfc1X36DvRlf22Lg31VTtENYmo6x7NFwpTlNoVUxv72c_CS-dYa9WFn_IDJmnkxdje-8VtyGHLlaVWCV21zLicWzvCCMdEZj82buWx9i0d1Ekz45BGZlqlFrCmtqpXc4FdtO-7b0X79q0_PkKHPlzHD872x2hHlSfoYOgXJJyiF0CAHQK80LhGgAEBNghwjQA7BHUP7A1sDnIIztDk-Wn8OAh8dYpgGZO0CjSnKhOKwni3SAUpEs4kjbIkpEVOBOU2MtYwdiFRRIhkSS5lAX-KhzLRGcviHtotF6U6Rzjm8CjxIo5UyqiCkJ2AW5Ra5ZnQIafRBeo5I8yWLgXJzFvn8ruGK9Td3AHXaE_DHa9uIHyqxK01_SdwNh4a |
link.rule.ids | 783 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+choice+of+prodrugs+for+gene+directed+enzyme+prodrug+therapy+of+cancer&rft.jtitle=Gene+therapy&rft.au=Connors%2C+T+A&rft.date=1995-12-01&rft.issn=0969-7128&rft.volume=2&rft.issue=10&rft.spage=702&rft_id=info%3Apmid%2F8750009&rft_id=info%3Apmid%2F8750009&rft.externalDocID=8750009 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0969-7128&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0969-7128&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0969-7128&client=summon |